158 related articles for article (PubMed ID: 35274709)
1. Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices.
Klink AJ; Marshall LZ; Aly A; Seal B; Healey MJ; Feinberg B
Oncologist; 2022 Mar; 27(3):e265-e272. PubMed ID: 35274709
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
[TBL] [Abstract][Full Text] [Related]
3. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
[TBL] [Abstract][Full Text] [Related]
6. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
[No Abstract] [Full Text] [Related]
7. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
[TBL] [Abstract][Full Text] [Related]
8. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.
Lin CL; Chien RN; Chen LW; Chu YD; Yeh CT
Cancer Biomark; 2023; 36(3):251-266. PubMed ID: 36938726
[TBL] [Abstract][Full Text] [Related]
9. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
10. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Wang L; Peng Y; Qin S; Wan X; Zeng X; Li S; Liu Q; Tan C
PLoS One; 2023; 18(4):e0279786. PubMed ID: 37053300
[TBL] [Abstract][Full Text] [Related]
11. Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies.
Grivas P; Huber C; Pawar V; Roach M; May SG; Desai I; Chang J; Bharmal M
Clin Genitourin Cancer; 2022 Apr; 20(2):114-122. PubMed ID: 34903481
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
13. Sequencing Systemic Therapy in Hepatocellular Carcinoma.
Ponvilawan B; Roth MT
Curr Treat Options Oncol; 2023 Nov; 24(11):1580-1597. PubMed ID: 37843628
[TBL] [Abstract][Full Text] [Related]
14. Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States.
Li D; Gruber SB; Iyer S; Gupta S; Tejani M
World J Gastrointest Oncol; 2023 Oct; 15(10):1796-1806. PubMed ID: 37969411
[TBL] [Abstract][Full Text] [Related]
15. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings.
Zu K; Arunachalam A; Hohlbauch A; Silver M; Robert N
Immunotherapy; 2023 Nov; 15(16):1375-1387. PubMed ID: 37694560
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation.
Cowey L; Chen CI; Aguilar KM; Davies K; LaFontaine PR; Fury MG; Bowler T; Golozar A; Jalbert JJ
Dermatol Ther (Heidelb); 2022 May; 12(5):1211-1224. PubMed ID: 35507216
[TBL] [Abstract][Full Text] [Related]
17. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
Perera S; Kelly D; O'Kane GM
Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy of liver cancer.
Demir T; Lee SS; Kaseb AO
Adv Cancer Res; 2021; 149():257-294. PubMed ID: 33579425
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
Furuse J; Ueno M; Ikeda M
Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
